- Home
- MDXH
MDXH
MDxHealth SA
as 07-26-2024 4:00pm EST
Stocks
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
| Founded: | 2003 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | 76.7M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 24.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $4.64 | Next Earning Date: | 08-21-2024 |
| Revenue: | $75,327,000 | Revenue Growth: | 65.02% |
| Revenue Growth (this year): | 22.19% | Revenue Growth (next year): | 14.13% |
Latest MDxHealth SA News
MDXH Breaking Stock News: Dive into MDXH Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance
GlobeNewswire
19 days ago
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
2 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
2 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
2 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
2 months ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Business Wire
2 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
Compare MDXH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDXH MDxHealth SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.